1.185

0.31% 0.005

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $1.185, with a volume of 400.26K. It is up +0.31% in the last 24 hours and up +15.89% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$1.19

Open:

$1.2

24h Volume:

400.26K

Relative Volume:

0.23

Market Cap:

$151.36M

Revenue:

$79.18M

Net Income/Loss:

$-136.99M

P/E Ratio:

-1.1235

EPS:

-1.0547

Net Cash Flow:

$-120.11M

1W Performance:

+15.89%

1M Performance:

+15.89%

6M Performance:

-66.28%

1Y Performance:

-58.12%

1-Day Range:

$1.145

$1.21

1-Week Range:

$1.015

$1.23

52-Week Range:

$0.7796

$4.98

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

193

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	1.19	136.09M	79.18M	-136.99M	-120.11M	-1.0547
VRTX Vertex Pharmaceuticals Inc	527.99	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.54	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.19	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.63	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.17	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Jul 01, 2026

ADC Therapeutics Announces New Employee Inducement Grant - PR Newswire

Jul 01, 2026

Jun 30, 2026

ADC Therapeutics Completes Enrollment in LOTIS-7, Advancing ZYNLONTA-Glofitamab Combination in DLBCL - BioPharm International

Jun 30, 2026

ADC Therapeutics completes LOTIS-7 trial enrollment - grafa.com

Jun 30, 2026

ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study - marketscreener.com

Jun 30, 2026

ADC Therapeutics completes enrollment in LOTIS-7 trial - Investing.com

Jun 30, 2026

ADC Therapeutics completes enrollment in LOTIS-7 trial By Investing.com - Investing.com Canada

Jun 30, 2026

ADC Therapeutics ends enrollment in ZYNLONTA combo trial for lymphoma - Stock Titan

Jun 30, 2026

Jun 29, 2026

ADC Therapeutics updates trial strategy, shares react to oncology shift - AD HOC NEWS

Jun 29, 2026

ETFs Investing in ADC Therapeutics Ltd Stocks - TradingView

Jun 29, 2026

ADC Therapeutics SA(NYSE: ADCT) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

ADC Therapeutics SA(NYSE: ADCT) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

ADCT stock plunges on safety concerns despite positive lymphoma data - MSN

Jun 29, 2026

Jun 28, 2026

ADC Therapeutics SA(NYSE: ADCT) added to Russell 3000E Value Benchmark - marketscreener.com

Jun 28, 2026

ADCT Q3 2020 Earnings Call - BigGo ファイナンス

Jun 28, 2026

Jun 27, 2026

Enterprise value to revenue forward of ADC Therapeutics SA – NYSE:ADCT - TradingView

Jun 27, 2026

ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views - Yahoo Finance

Jun 27, 2026

Enterprise value to EBIT forward of ADC Therapeutics SA – NYSE:ADCT - TradingView

Jun 27, 2026

Jun 26, 2026

ADC Therapeutics Announces 17% Workforce Reduction and Strategic Reorganization to Boost ZYNLONTA® Growth and Regulatory Milestones - Minichart

Jun 24, 2026

Bronstein, Gewirtz & Grossman, LLC (ADCT) Investigation: Bronstei - The National Law Review

Jun 24, 2026

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details - Stocktwits

Jun 24, 2026

ADC Therapeutics plans 17% workforce cut to save ~$10M annually, $3M one-time charges - TradingView

Jun 24, 2026

ADC Therapeutics (NYSE: ADCT) trims workforce 17% to back ZYNLONTA trials and extend cash runway - Stock Titan

Jun 24, 2026

ADC Therapeutics to cut 17% of workforce, save $10M annually - Investing.com Australia

Jun 24, 2026

ADC Therapeutics Announces Strategic Reorganization to Support Z - GuruFocus

Jun 24, 2026

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities - 富途牛牛

Jun 24, 2026

أعلنت شركة ADC Therapeutics عن إعادة هيكلة استراتيجية لدعم فرص نمو دواء ZYNLONTA® والأولويات التنظيمية. - Sahm

Jun 24, 2026

Jun 23, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 23, 2026

2026-06-23 | Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Shareholders to Inquire about Securities Investigation | NYSE:ADCT | Press Release - Stockhouse

Jun 23, 2026

Tango Therapeutics Appoints New Board Member - Intellectia AI

Jun 23, 2026

Jun 22, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 22, 2026

2026-06-22 | Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Shareholders to Connect | NYSE:ADCT | Press Release - Stockhouse

Jun 22, 2026

Jun 21, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jun 21, 2026

Jun 19, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jun 19, 2026

Jun 18, 2026

Why ADC Therapeutics’ loncastuximab tesirine is still on oncologists’ radar - AD HOC NEWS

Jun 18, 2026

ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN

Jun 18, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 18, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire

Jun 18, 2026